| Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers EC Page, EK Bancroft, MN Brook, M Assel, MH Al Battat, S Thomas, ... European urology 76 (6), 831-842, 2019 | 251 | 2019 |
| Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients A George, D Riddell, S Seal, S Talukdar, S Mahamdallie, E Ruark, ... Scientific reports 6 (1), 29506, 2016 | 232 | 2016 |
| Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants S Li, V Silvestri, G Leslie, TR Rebbeck, SL Neuhausen, JL Hopper, ... Journal of Clinical Oncology 40 (14), 1529-1541, 2022 | 229 | 2022 |
| Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group D Mandelker, M Donoghue, S Talukdar, C Bandlamudi, P Srinivasan, ... Annals of Oncology 30 (8), 1221-1231, 2019 | 200 | 2019 |
| Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D X Yang, H Song, G Leslie, C Engel, E Hahnen, B Auber, J Horváth, K Kast, ... JNCI: Journal of the National Cancer Institute 112 (12), 1242-1250, 2020 | 181 | 2020 |
| Clinical practice guidelines for BRCA1 and BRCA2 genetic testing P Pujol, M Barberis, P Beer, E Friedman, JM Piulats, ED Capoluongo, ... European Journal of Cancer 146, 30-47, 2021 | 158 | 2021 |
| A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations JRF Wilson, AC Bateman, H Hanson, Q An, G Evans, N Rahman, ... Journal of medical genetics 47 (11), 771-774, 2010 | 146 | 2010 |
| BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years L Robertson, H Hanson, S Seal, M Warren-Perry, D Hughes, I Howell, ... British journal of cancer 106 (6), 1234-1238, 2012 | 130 | 2012 |
| Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants DR Barnes, MA Rookus, L McGuffog, G Leslie, TM Mooij, J Dennis, ... Genetics in Medicine 22 (10), 1653-1666, 2020 | 120 | 2020 |
| Consensus for genes to be included on cancer panel tests offered by UK genetics services: guidelines of the UK Cancer Genetics Group A Taylor, AF Brady, IM Frayling, H Hanson, M Tischkowitz, C Turnbull, ... Journal of medical genetics 55 (6), 372-377, 2018 | 118 | 2018 |
| Hereditary leiomyomatosis and renal cell cancer: clinical, molecular, and screening features in a cohort of 185 affected individuals C Forde, DHK Lim, Y Alwan, G Burghel, L Butland, R Cleaver, A Dixit, ... European urology oncology 3 (6), 764-772, 2020 | 84 | 2020 |
| A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study EK Bancroft, EC Page, MN Brook, S Thomas, N Taylor, J Pope, J McHugh, ... The Lancet Oncology 22 (11), 1618-1631, 2021 | 75 | 2021 |
| Deletion of the distal long arm of chromosome 10; is there a characteristic phenotype? A report of 15 de novo and familial cases M Irving, H Hanson, P Turnpenny, C Brewer, CM Ogilvie, A Davies, J Berg American Journal of Medical Genetics Part A 123 (2), 153-163, 2003 | 72 | 2003 |
| Comprehensive cancer-predisposition gene testing in an adult multiple primary tumor series shows a broad range of deleterious variants and atypical tumor phenotypes J Whitworth, PS Smith, JE Martin, H West, A Luchetti, F Rodger, G Clark, ... The American Journal of Human Genetics 103 (1), 3-18, 2018 | 66 | 2018 |
| Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls S Saya, E Killick, S Thomas, N Taylor, EK Bancroft, J Rothwell, S Benafif, ... Familial cancer 16, 433-440, 2017 | 65 | 2017 |
| Telomere shortening in Fanconi anaemia demonstrated by a direct FISH approach H Hanson, CG Mathew, Z Docherty, C Mackie Ogilvie Cytogenetics and cell genetics 93 (3-4), 203-206, 2001 | 64 | 2001 |
| Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations Z Kuzbari, C Bandlamudi, C Loveday, A Garrett, M Mehine, A George, ... Annals of Oncology 34 (3), 215-227, 2023 | 63 | 2023 |
| Clinical likelihood ratios and balanced accuracy for 44 in silico tools against multiple large-scale functional assays of cancer susceptibility genes C Cubuk, A Garrett, S Choi, L King, C Loveday, B Torr, GJ Burghel, ... Genetics in Medicine 23 (11), 2096-2104, 2021 | 57 | 2021 |
| The value of clinical criteria in identifying patients with X-linked Alport syndrome H Hanson, H Storey, J Pagan, F Flinter Clinical Journal of the American Society of Nephrology 6 (1), 198-203, 2011 | 55 | 2011 |
| Combining evidence for and against pathogenicity for variants in cancer susceptibility genes: CanVIG-UK consensus recommendations A Garrett, M Durkie, A Callaway, GJ Burghel, R Robinson, J Drummond, ... Journal of medical genetics 58 (5), 297-304, 2021 | 50 | 2021 |
